Annexin: Additional confirmation of effect signal and update on cash runway - Redeye

Redeye endorses yesterday's promising effect signal in 6 out of 8 patients followed for at least 3 months or longer in the ongoing phase II RVO study, showing no need for multiple doses of the standard of care anti-VEGFs, which we think is a good confirmation of the previous effect signal reported last year. In today’s report, the company mentioned that it has secured a loan facility from a few significant shareholders of up to SEK15m, which we think is reassuring given the company previously short cash runway. We will discuss the results and the report further in a research update to be published on Monday.

Länk till analysen i sin helhet: https://www.redeye.se/research/976927/annexin-additional-confirmation-of-effect-signal-and-update-on-cash-runway?utm_source=finwire&utm_medium=RSS